INV 290
Alternative Names: INV-290Latest Information Update: 02 Aug 2023
At a glance
- Originator INVENT Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Neuroendocrine tumours
Most Recent Events
- 31 Jul 2023 Invent Pharmaceuticals has patent protection for small molecules prior July 2023 (Invent Pharmaceuticals website, July 2023)
- 14 Jul 2023 Investigation in Neuroendocrine tumours in USA (PO) (INVENT Pharmaceuticals pipeline, July 2023)